Press Release

India Olmesartan Market to grow at a steady rate During the Forecast Period

Growing prevalence of hypertension is expected to drive the growth of India Olmesartan market.

According to TechSci Research report, India Olmesartan Market By Dose (10 mg, 20 mg, 40 mg, Others), By Source (In-house v/s Contract Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By Application (High Blood Pressure, Heart Failure, Diabetic Kidney Disease Others), By End User (Adult v/s Pediatric), By Company, By Region, Forecast & Opportunities, FY2026, the India Olmesartan market is expected to grow at a steady rate during the forecast period for the treatment of essential hypertension. Olmesartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). It generally relaxes the blood vessels so that blood can flow more easily. Olmesartan is also used to treat heart failure as well as diabetic nephropathy.  This in turn is expected to fuel the market growth through FY2026. However, side-effects associated with drug consumption such as feeling dizzy, headache or flu-like symptoms, or pain in your back, bones or joints, feeling sick (nausea), stomach ache or indigestion, diarrhea, swollen feet, ankles or legs, urinary tract infection (UTI) can restrict the market growth over the next few years. Moreover, in certain cases itching, a rash, or lumps on skin, or tiny red spots under the skin are also observed. This can further reduce the usage and application of the drug thereby hindering the market growth during the forecast period.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on" India Olmesartan Market"

https://www.techsciresearch.com/report/india-olmesartan-market/5149.html

The India Olmesartan market is segmented based on dose, source, distribution channel, application, end user, company, and region. Based on application, the market can be fragmented into high blood pressure, heart failure, diabetic kidney disease, others. The high blood pressure segment is expected to dominate the market in the forthcoming years on account of rising count of patients having high blood pressure. Based on source, the market can be categorized into in-house v/s contract manufacturing organizations. The in-house segment dominated the market until 2017 as most of the leading companies focus on in house production. In terms of dose, the market is split into 10 mg, 20 mg, 40 mg, Others. Among them, 20 mg dose segment is projected to dominate the market in the next 5 years as 20 mg dose is the recommended starting dose of Olmesartan for adults and children.

Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Cadila Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Unichem Laboratories Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Lupin Laboratories Ltd. (Pinnacle), Abbott Healthcare Pvt. Ltd., Morepen Laboratories Ltd and others are some of the leading players operating in India Olmesartan market. Companies operating in the market are using organic strategies such as product launches, new technologies, pharma licensing deals, mergers and acquisitions, research collaborations to boost their share and increase their geographic reach.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5149

Customers can also request for 10% free customization on this report.

India Olmesartan market is expected to witness growth during the forecast period as it is used to treat high blood pressure (hypertension) and therefore helps to prevent strokes, heart attacks, and kidney problems in an individual. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which performs an essential part in haemostasis and regulation of kidney, vascular, and cardiac functions. This is further expected to create lucrative opportunities for the market growth of “India Olmesartan market over the next five years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.

India Olmesartan Market By Dose (10 mg, 20 mg, 40 mg, Others), By Source (In-house v/s Contract Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By Application (High Blood Pressure, Heart Failure, Diabetic Kidney Disease Others), By End User (Adult v/s Pediatric), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India Olmesartan market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India Olmesartan market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

 

Tel: +1-646-360-1656

 

Email: sales@techsciresearch.com

 

Relevant News